Fluticasone furoate plus vilanterol in patients with moderate persistent asthma: a cost-utility analysis.

Jefferson Antonio BuendiaDiana Guerrero Patiño

Published in: The Journal of asthma : official journal of the Association for the Care of Asthma (2022)

FF/VI is more cost-effective than FP/Salm. The evidence supports using FF/VI therapy in Colombia, and the study should be replicated in other middle-income countries.

Keyphrases

chronic obstructive pulmonary disease
physical activity
lung function
high intensity
cystic fibrosis
air pollution
cell therapy
smoking cessation
data analysis